title: Selective cyclooxygenase-2 inhibitor compound 11b improves haloperidol-induced catatonia by enhancing the striatum dopaminergic neurotransmission.
abstract: The aim of this research was to investigate the Cyclooxygenase-2 (COX-2) selective inhibition effect on haloperidol-induced catatonia. In this study, the effect of orally, acutely and Sub-chronically administrations of compound 11b [1-(phenyl)-5-(4-methylsulfonylphenyl)-2-ethylthioimidazole] (2, 4 and 8 mg/kg), a newly selective COX-2 inhibitor, was investigated against the haloperidol-induced catatonia phenomenon comparing to the standard drug scopolamine (1 mg/Kg) followed by microdialysis analysis of Striatum dopaminergic neurotransmission. The results showed a great potency for compound 11b in improvement of catalepsy followed by enhancing the dopaminergic neurotransmission p < 0.05. In addition, our statistical analysis showed that the protective effect of compound 11b against haloperidol-induced catatonia was both dose- and time-dependent. These findings are additional pharmacological data that suggest the effectiveness of compound 11b in treatment of schizophrenic drug overdoses and also Parkinson's disease (PD) affiliated rigidity.
authors.affiliation: Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Aghasadeghi
authors.forename: Seyyed Davar
authors.initials: SD
authors.lastname: Siadat
authors.forename: Mehdi
authors.initials: M
authors.lastname: Shafiee Ardestani
authors.forename: Ali
authors.initials: A
authors.lastname: Jabbari Arabzadeh
authors.forename: Mitra
authors.initials: M
authors.lastname: Elmi
authors.forename: Hadi
authors.initials: H
authors.lastname: Fathi Moghaddam
keywords: Catalepsy; Compound 11b; Dopaminergic neurotransmission; Nigrostriatal; Parkinson’s disease; Selective COX-2 inhibitor